Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics (Q74233692)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10962218%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

title

Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10962218%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference

Y K Kim

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10962218%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

L Kim

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10962218%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

M S Lee

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10962218%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

publication date

1 September 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10962218%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

published in

Schizophrenia Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10962218%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

volume

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10962218%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10962218%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

165-175

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10962218%20AND%20SRC:MED&resulttype=core&format=json

Psychoneuroimmunology: interactions between the nervous system and the immune system

9 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Interleukin-2 modulates evoked release of [3H]dopamine in rat cultured mesencephalic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Serum cytokine concentrations in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Differential effect of mixed D1/D2 and selective D2 dopaminergic antagonists on mouse T and B lymphocyte proliferation and interleukin production in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Biological significance of soluble IL-2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Molecular pathology of schizophrenia: more than one disease process?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Dopamine in schizophrenia: a review and reconceptualization

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

The effects of anticoagulation and processing on assays of IL-6, sIL-6R, sIL-2R and soluble transferrin receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Increased serum interleukin 2 receptor concentration in schizophrenic and brain-damaged subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Clinical and laboratory evidence of autoimmunity in acute schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Abnormalities in serum concentrations of interleukin-2, interferon-alpha and interferon-gamma in schizophrenia not detected

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Increased soluble interleukin 2 receptor levels in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Interleukin-2 as a neuroregulatory cytokine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

T-lymphocyte subpopulations in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Plasma levels of interleukin-1 beta and interleukin-6 in schizophrenia, other psychoses, and affective disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Decreased interleukin-2 production in Korean schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

A role for interleukin-2 in the regulation of striatal dopaminergic function

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Immunoautoradiographic localization of interleukin 2-like immunoreactivity and interleukin 2 receptors (Tac antigen-like immunoreactivity) in the rat brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Short and long-term immunosuppressive effects of clozapine and haloperidol.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Neurochemistry and neuroendocrinology of schizophrenia: a selective review

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

In vivo immunomodulatory effects of clozapine in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Elevated circulating levels of IL-6 in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Immunoregulators in the nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Elevated levels of soluble interleukin 2 receptors in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Influence of collection and separation of blood samples on plasma IL-1, IL-6 and TNF-alpha concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Immunological dysfunction in schizophrenia: a systematic approach.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

The role of 5-HT2A receptors in antipsychotic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

High-performance liquid chromatography of biogenic amines and metabolites in brain, cerebrospinal fluid, urine and plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Serum interleukin-6 in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

The macrophage-T-lymphocyte theory of schizophrenia: Additional evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Measuring cytokine levels in blood

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Neurodynamics of abnormalities in cerebral metabolism and structure in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2899%2900171-1

7 January 2021

10.1016/S0920-9964(99)00171-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10962218%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference